LDS/Medical Tests/Cyclin-Dependent Kinase-Like 5 (CDKL5) Mutation Analysis

Cyclin-Dependent Kinase-Like 5 (CDKL5) Mutation Analysis

Cyclin-dependent kinase-like 5 (CDKL5) is a serine threonine kinase that interacts with methyl-CpG-binding protein 2 (MECP2) protein, which has an important role in the functionality of neurons and synapses. It is important in the normal development of the brain. Germline mutations in the CDKL5 gene are associated with early-onset intractable seizures and severe developmental delay and result in a range of clinical phenotypes, including X-linked infantile spasm syndrome (ISSX) and atypical Rett syndrome.

Individuals with germline mutations in either the MECP2 or CDKL5 genes may have overlapping clinical features, as both genes are involved in the same molecular pathway and exhibit similar expression patterns during development. Patients with ISSX have frequent seizures during the first year of life in addition to other intellectual abnormalities and lack of developmental progression.

Rett syndrome with mostly de novo mutation in MECP2 gene is characterized by mental retardation, seizures in around 50% of cases, other neurological disabilities, and mild skeletal abnormalities.

This disease shows X-linked dominant inheritance and is normally limited to females and is lethal in males. More than 70 mutations have been described in the CDKL5 gene resulting in missense, nonsense, splice and frameshift mutations. Phenotypic variability by this mutation in females is explained by random lyonization (X-inactivation).

This is an important kinase in the sensory pathway and pain signaling, and abnormalities are associated with Alzheimer’s disease.

  • To confirm a clinical diagnosis of a CDKL5-related disorder in individuals with infantile seizures, ISSX, MECP2-negative atypical Rett syndrome
  • As an aid in diagnosis of autism, or mental retardation and seizure disorder mainly related to CDKL5 mutations

Identification of a known CDKL5 mutation in a symptomatic individual predicts the presence of a CDKL5-related disorder. Clinical phenotypes may vary; however, in most of the cases CDKL5 mutations genotypes correlate with clinical signs and symptoms. Presence of silent mutations and inconsistent genotype-phenotype correlation should be considered.

Negative results for CDKL5 mutation in a clinically affected individual decreases, but does not exclude, a diagnosis of a CDKL5-related disorder.

Mutation not detected.

Negative results for CDKL5 mutation in a clinically affected individual decreases, but does not exclude, a diagnosis of a CDKL5-related disorder.

 

 

DNA sequencing is the gold standard method. Additional methods include: multiplex ligation-dependent probe amplification (MLPA), denaturing high-performance liquid chromatography (dHPLC), single stranded conformation polymorphism (SSCP), high resolution melting analysis (HRMA), which are rapid and reliable scanning methods.

Whole blood collected with anticoagulants (EDTA or purple top tube or any anticoagulant collection tube).

Stability

  • Ambient: 5 days
  • Refrigerated: 7 days
Electroencephalogram (hypsarrhythmia pattern in X-linked infantile spasm syndrome). Mutation screening of *MECP2* gene, Chromosomal analysis.
2-5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login